The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

Researchers say they've discovered an already approved migraine drug that can stop symptoms hours before a severe headache ...